Akums Drugs and Pharmaceuticals Ltd - 544222 - Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting24-08-2024
24-08-2024
Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to requirement of Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, this is to inform you that Akums Drugs & Pharmaceuticals Limited will be hosting earnings/analysts conference call on Friday, August 30, 2024 at 4:00 PM IST for limited reviewed un-audited financial results of Q1 FY25.23-08-2024
Akums Drugs and Pharmaceuticals Ltd - 544222 - Commencement Of Commercial Production Of Second Production Facility By Wholly Owned Subsidiary Company - Akums Healthcare Limited Of The Company
Commencement of Commercial Production of second production facility by wholly owned subsidiary company - Akums Healthcare Limited, of the company.22-08-2024
Akums Drugs and Pharmaceuticals Ltd - 544222 - Board Meeting Intimation for Considering And Approving The Un-Audited (Standalone & Consolidated) Financial Results For The Quarter Ended 30Th June, 2024.
Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/08/2024 ,inter alia, to consider and approve the Un-audited (Standalone & Consolidated) Financial Results for the quarter ended 30th June, 2024.21-08-2024
Akums Drugs and Pharmaceuticals Ltd - 544222 - Clarification On Price Movement
Clarification on Price Movement20-08-2024
Akums Drugs and Pharmaceuticals Ltd - 544222 - Clarification sought from Akums Drugs and Pharmaceuticals Ltd
The Exchange has sought clarification from Akums Drugs and Pharmaceuticals Ltd on August 19, 2024 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.20-08-2024
Akums Drugs and Pharmaceuticals Ltd - 544222 - Code Of Practices And Procedures For Fair Disclosure Of Unpublished Price Sensitive Information
Code of Practice and Procedure for fair disclosure of Unpublished Price Sensitive Information07-08-2024
Akums Drugs and Pharmaceuticals Ltd - 544222 - Closure of Trading Window
Trading Window Closure06-08-2024
Akums Drugs and Pharmaceuticals Ltd - 544222 - Listing of Equity Shares of Akums Drugs and Pharmaceuticals Ltd
Trading Members of the Exchange are hereby informed that effective from August 06, 2024, the equity shares of Akums Drugs and Pharmaceuticals Ltd (Scrip Code: 544222) are listed and admitted to dealings on the Exchange in the list of ''B'' Group Securities. For further details please refer to the notice no. 20240805 dated August 05, 2024.06-08-2024
Akums Drugs and Pharma's IPO gets fully-subscribed on Day 1 of offer
The initial public offer of Akums Drugs and Pharmaceuticals got fully-subscribed on the first day of subscription on Tuesday. The Rs 1,875-crore initial share sale received bids for 2,07,92,684 shares, as against 1,51,62,239 shares on offer, translating to 1.37 times subscription, as per the NSE data. The issue will conclude on August 1. The quota for Retail Individual Investors (RIIs) received 3.35 times subscription, while the Non Institutional Investors part got subscribed 1.96 times. The portion for qualified institutional buyers (QIBs) received 43 per cent subscription. The IPO is a combination of a fresh issue of equity shares worth Rs 680 crore and an offer-for-sale (OFS) of 1.73 crore shares valued at Rs 1,177 crore at the upper-end of the price band by promoters and an existing investor. Those selling shares in the OFS are Sanjeev Jain, Sandeep Jain and Ruby QC Investment Holdings Pte Ltd. The public issue has a price range of Rs 646 to Rs 679 per share Akums Drugs and31-07-2024